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ABSTRACT
Purpose To evaluate the kinetics of topically applied
clobetasol-17-propionate (CP-17) in lesional and non-
lesional psoriatic skin when released from a commercially
available low-strength cream using in vivo dermal open-flow
microperfusion (dOFM).
Methods Twelve patients received Dermovate® cream (CP-
17, 0.05%) on small lesional and non-lesional skin test sites for
14 days, once daily. On day 1 and 14, dOFM samples were
continuously taken in the dermis for 24 h post-dose and ana-
lyzed by LC-MS/MS. Probe depths were assessed by 50MHz
ultrasound scanning.
Results Mixed-effects modelling identified skin condition,
treatment duration and probe-depth as kinetics determining
variables. The time- and depth-resolved intradermal data re-
vealed (i) slower penetration of CP-17 into lesional than into
non-lesional skin, (ii) normalized (faster) skin penetration after
repeated dosing, and (iii) no CP-17 accumulation within the
dermis independently of the skin condition.
Conclusions Intradermal investigation of a highly lipophilic
drug released from low-strength cream was successfully per-
formed by using dOFM and timely and spatially, i.e., probe-
depth dependent, resolved kinetic data were delivered. These
data support the assumption that the thickened psoriatic stra-
tum corneum might act as trap compartment which lowers
the skin penetration rate for lipophilic topical drugs.
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ABBREVIATIONS
AUC Area Under the CP-17 concentration time Curve
CP-17 Clobetasol-17-propionate
dOFM Dermal open flow microperfusion
LLOQ Lower Limit of Quantification
MD Microdialysis
SC Stratum Corneum
TSS Total Sum Score
INTRODUCTION
Topical corticosteroids play a major role in the therapy of
inflammatory skin disorders (1, 2). These topically applied ste-
roids are highly effective, but their delivery into the skin is
sometimes rather inefficient (2). Additionally, the role of the
stratum corneum (SC) in different skin diseases regarding the
kinetics of such topically applied lipophilic drugs remains un-
clear up to now, because in vivo sampling of such drugs is still
challenging. Sufficiently sensitive, accurate and well-tolerable in
vivo sampling methods are not commonly available (3). Several
existing in vivo sampling methods, such as punch biopsies (4),
suction blister (4), or tape stripping (5, 6) are either highly in-
vasive or do not provide any information on the drug concen-
tration from the site of action. Dermal microdialysis (MD) (7) is
minimally invasive and capable of directly measuring the rate
and extent of drug absorption at or near the site of action in the
skin (8), but for intradermal sampling of topically applied drugs,
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MD has certain limitations. Typical topically applied drugs are
lipophilic and commercially available topical formulations con-
tain potent active ingredients in low concentration, resulting in
concentrations of the recovered drug in the MD sample that
may even lie below the limit of quantification (9). Furthermore,
the pore size of the semipermeable MD membrane restricts
sampling of molecules by excluding largemolecules. Open flow
microperfusion (OFM) (10), in contrast to microdialysis, uses a
fully permeable open mesh and has been adapted for dermal
sampling (11, 12). It overcomes the limitations of MD when
sampling lipophilic topical drugs (11, 13) and is thus capable of
assessing topical glucocorticoid kinetics, when released from a
commercial low-strength cream, in vivo.
Clobetasol-17-propionate (CP-17) was used as study drug.
CP-17 is a highly potent corticosteroid for topical treatment of
psoriasis (2, 14) and commercially available as cream with low
strength (0.05%). Although CP-17 is widely used, data on the
penetration behavior of this drug into skin is rare. One study
performed by Au et al. (15) investigated the feasibility of CP-17
sampling in the skin, but they applied highly concentrated CP-
17 in ethanolic solution, because the high lipophilicity of CP-
17 (LogP=3.49) precluded the use of a commercial formula-
tion for MD sampling. A study on the penetration behavior of
a topical lipophilic drug into healthy and psoriatic lesional skin
using tape-stripping followed by skin punch biopsy was per-
formed by Rony et al. (unpublished data, presented at Groupe
de Métabolisme et Pharmacocinétique Meeting 2011, Paris).
Their results revealed diminished drug penetration into pso-
riatic skin due to accumulation of the drug in the SC. Thus,
they assumed that the thickened SC might act as trap com-
partment of the skin for lipophilic entities. Also in a previous
dOFM study in psoriatic patients, using amoderately lipophil-
ic drug, concentrations of the anti-psoriatic drug candidate
BCT194 were found to be lower in psoriatic lesional skin than
in non-lesional skin (12).
The aim of the current study was to evaluate the kinetics of
highly lipophilic topical CP-17 in vivo in lesional and non-
lesional psoriatic skin when released from a low strength
cream and to elucidate the role of the SC in psoriasis by using
timely and spatially, i.e., probe-depth resolved kinetic data.
MATERIALS AND METHODS
Topical Treatment
Clobetasol-17-propionate (CP-17) is a highly potent cortico-
steroid (US class I, Europe class IV) that activates glucocorti-
coid receptors and exhibits anti-inflammatory and immuno-
suppressive activities. CP-17 is widely used for topical treat-
ment of psoriasis (14) and it was applied as commercial cream
of low-strength (Dermovate® Cream, 0.05% CP-17,
GlaxoSmithKline Pharma GmbH, Vienna, Austria).
Dermovate® Cream was applied once daily from day 1 to
day 14 to one lesional and one non-lesional test site of 7.7 cm2
each at a topical dose of 15 mg/cm2. On days 1 and 14, when
dOFM sampling was continuously performed from baseline to
24 h post-dose, the cream remained on the skin and the test site
was protected by a non-occlusive dressing. On the days without
investigation by dOFM, the topical dose was applied once and
excess of cream was removed at approximately 4 h post-dose.
24 h Dermal OFM Sampling
Continuous intradermal sampling was initiated and per-
formed as described in (12, 16), by using CE-certified
dOFM materials. The dOFM probe was tested for potential
unspecific adsorption of CP-17 and the absence of any adsorp-
tive losses was confirmed.
Prior to probe insertion, the skin was cooledwith an sterile ice
bag to avoid pain (16). Three linear dOFM sampling probes
(Type DEA15001, OD 0.32 mm, 15 mm open-mesh with inte-
grated 0.5 mm insertion needle) were inserted into a lesional test
site and three probes into a non-lesional test site. Following
insertion, the three adjacent probes were continuously perfused
in a push-pull manner with sterile perfusate (physiological saline
solution including 1%Human SerumAlbumin) at a flow rate of
1 μL/min using a single wearable OFM pump (Type MPP101
with sterile fluidic kit). The dermal interstitial fluid samples were
collected hourly from baseline to 24 h post-dose. The dermal
OFM setup is shown in Fig. 1.
Patients
The study was approved by the Ethical Committee of the
Medical University of Graz and the Austrian health authorities
(AGES) and performed in accordance with the Declaration of
Helsinki and Good Clinical Practice. Twelve psoriatic patients
with a diagnosis of stable plaque type psoriasis for at least
6 months and at least two psoriatic plaques on the upper ex-
tremities or proximal lower extremities were recruited
(Caucasian, 9 men and 3 women, 40.2±5.8 years) and gave
written informed consent. The plaque Total Sum Score (TSS;
erythema+ induration/plaque elevation+scaling) had to be≥6
with each item scoring 2 or 3 (moderate to severe) with a max-
imum of 2 for scaling. Subjects were otherwise healthy and
screened for eligibility by assessing their medical history, physical
parameters and laboratory parameters. Concomitant medica-
tion was not allowed, and women had to use contraception.
Study Design
The study was designed as a single-center, open-label explor-
atory phase I trial and conducted at the Medical University of
Graz, Austria. In the pilot phase, topical CP-17 penetration
was investigated in four subjects to identify the quantification
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limit for CP-17 from dOFM samples. In the main clinical
study, eight subjects were dosed with CP-17 from day 1 to
day 14, daily. dOFM was performed on day 1 and day 14.
Patients were admitted to the clinic at 7 am (day 1). One
lesional and one non-lesional site were marked on the skin,
and three dOFM probes were inserted into the dermis of each
site for continuous sampling as described above. After a run-in
period of 60 min to allow the insertion trauma to subside (17),
a baseline (pre-dose) sample was collected. At 11 am (t=0),
Dermovate® cream was applied to each site, as described
above. dOFM samples were collected hourly, immediately
frozen at −80°C and kept at −80°C until analysis. Sampling
was terminated 24 h post-dose. Probe depth and the exact
position in the skin were assessed in duplicate by 50 MHz
ultrasound scanning (DUB-USB, Taberna Pro Medicum,
Lüneburg, Germany) as described in detail previously (16).
After probe removal, sites were inspected and covered with
light dressings. On days 3–13, patients revisited the study cen-
ter once daily, received the topical dose, left the clinic 1 h post-
dose and were asked to remove the excess of cream approxi-
mately 4 h post-dose. On day 14, patients were admitted to
the clinic in the morning. The same protocol as on day 1 was
followed, but with two methodological alterations taking the
reinsertion of dOFM to the now previously used test sites into
account: First, the probes were shifted by 5 mm relative to
their position on day 1. Second, the probe insertion points
outside of the application zones were cleaned thoroughly with
gauze, followed by slight tape stripping to reduce risk of probe
contamination with residual drug in the SC. On day 14, the
clinical improvement of CP-17 treated lesions was also evalu-
ated using the plaque Total Sum Score (TSS). The follow-up
visit was scheduled between days 18 and 25. An overview of
the study days and procedures is given in Fig. 2.
Sample Analysis and Data Management
Baseline sample and six pooled post-dose samples (0–4 h, 4–
8 h, 8–12 h, 12–16 h, 16–20 h, 20–24 h) were analyzed to
assess intradermal kinetics. CP-17 was measured after liquid-
liquid extraction by LC-MS/MS in selected multiple-reaction
monitoring (MRM) positive ion mode. Internal standard (CP-
17-d3), 15 mM NH4OH (50 μL), and diethylether/hexane
80/20 (400 μL) were added to 50 μL of standards or samples.
The samples were vortexed and centrifuged. Then, the organ-
ic layer was removed and evaporated to dryness under vacu-
um. The residue was redissolved in 30% acetonitrile (20 μL)
and subsequently analyzed. The measurement was performed
on a U300 Ultimate HPLC system (Dionex) coupled to a
TSQ Ultra AM triple quadrupole mass spectrometer
(Thermo). The separation was carried out on a Zorbax SB-
C18 (0.5 × 35 mm) column (Agilent), with a flow rate of
50 μL/min and 7.5 μL injection volume using gradient elu-
tion (eluent A: water 0.1% formic acid; eluent B: acetontrile
0.1% formic acid). The gradient started with 40% eluent B
which was linearly increased to 90% within 2.0 min and kept
constant for until 4.5 min. The analyte was detected in MRM
mode (CP-17: 467.2−446.9 (3 eV), 467.2−372.9 (9 eV), 467.2
−354.9 (10 eV), 467.2−277.9 (17 eV), 467.2−262.9 (24 eV);
Internal standard: 470.2−372.8 (8 eV), 470.2−354.8 (10 eV),
470.2−277.90 (18 eV), 470.2−262.8 (17 eV). The Lower
Limit of Quantification (LLOQ) was 0.35 ng/mL.
For data management, we used an electronic case report
form (eCRF) within the OpenClinica Enterprise Edition
(OpenClinica, LLC 460 Totten Pond Road, Suite 200,
Waltham, MA 02451). OpenClinica had been fully validated
and it is 21 CFR Part 11 compliant.
Pharmacokinetic Analysis and Statistics
Only the 8 subjects of the main study were included in the
pharmacokinetic analysis. CP-17 concentration profiles were
checked for validity, considering the concentration gradient
from the skin surface (500 μg/ml) to the dermal interstitial fluid
(about 0.5 ng/ml) and the risk of probe contamination with
residual topical drug in the SC during reinsertion of probes on
day 14. For the pharmacokinetic analysis, the areas under the
CP-17 concentration time curves (AUCs) were calculated by
Fig. 1 Left: Scheme of dOFM setup. Themembrane-free dOFM probe within the dermis is continuously perfused and delivers interstitial fluid for further analysis.
Right: Wearable dOFM setup including the dOFM probe, a wearable push-pull pump, and a unit for sample collection.
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cumulating sample concentrations from 0 to 24 h or, in case of a
missing sample, by the standard trapezoidal method.
Outliers in CP-17 profiles were excluded when the outlying
value was <50% or >200% of the interpolated concentration.
All data were expressed as arithmetic mean±SD. All AUC-
values were log-transformed prior to data analysis. The log-
transformed AUC-values were tested for statistical signifi-
cance by means of two-factorial repeated measure ANOVAs
using BTime^ (BDay 1^ versus BDay 15^) and BSkin site^
(BLesional^ versus BNon-Lesional^) as within-subjects factors.
P-values <0.05 were considered statistically significant. In case
of a statistically significant ANOVA, paired t-tests were per-
formed to find the significant mean differences. For the inter-
pretation of these post-hoc tests on the raw data (i.e., non-
depth corrected data) the significance level was adjusted ac-
cording to Bonferroni. In order to keep the familywise error
rate at 0.05, we adjusted the significance level to 0.05/
4=0.0125. By applying this Bonferroni adjustment we follow-
ed a very conservative approach.
In order to analyze the effect of data treatment, the AUCs
were calculated from three different data sets: Data set 1: All
CP-17 raw data values below LLOQ were left unchanged;
Data set 2: All CP-17 values below LLOQ were set to
LLOQ; Data set 3: All CP-17 values below LLOQ were set
to LLOQ/2.
The dependency of CP-17 concentration on the depth was
identified in a stepwise approach:We (i) plotted the AUC data
versus probe-depth, (ii) searched for adjacent probes with dif-
ferent depths and counted the pairs for which the AUC-depth
relationship was true in a frequency analysis, and (iii)
compared the probe with the greatest and the smallest depth
per site with respect to the AUC, using paired t-tests. Finally, a
linear mixed effects model (iv) was fitted to the data, using
Log(AUC) as dependent variable, BTime^ and BSkin site^ as
fixed effects, BSubject^ as random effect, and BProbe-depth^
as covariate. Model simplification was performed by using
likelihood ratio tests, starting with the full model containing
all predictor variables.
The open source software package BR^ (Version 2.10.1)
was used for the statistical analysis.
RESULTS
CP-17 Treatment Effect and dOFM Tolerability
Study procedures and 24 h sampling periods were well toler-
ated by all subjects. No subjects dropped out and no serious
adverse events occurred. Daily topical treatment with CP-17
resulted in a visible improvement of psoriatic skin within
14 days. The plaque Total Sum Score (TSS) for the lesional
test site was reduced from 6.3±0.5 on day 1–2.4±1.4 on day
15 (p<0.001) and appeared as a pale rectangular area within
the otherwise unchanged psoriatic plaque.
CP-17 Profiling by dOFM
On day 1, CP-17 concentrations in the dermal interstitial fluid
of non-lesional skin reached the LLOQ at approximately 10 h
post-dose and maximum concentrations were observed at
Fig. 2 Study days with treatment regimen and protocol on the days of OFM investigation. CP-17 was dosed as Dermovate®Cream 0.05% once daily from day
1 to day 14. Following the doses on day 1 and day 14 the kinetics of CP-17 were followed in dermal interstitial fluid for 24 h by using dOFM.
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18 h post-dose (0.07–1.86 ng/ml, mean Cmax 0.61 ng/ml;
Fig. 3a). In lesional skin, the CP-17 levels steadily increased
on day 1, but most subjects did not reach the LLOQ during
the whole 24 h sampling period (range 0.09–0.42 ng/ml,
mean Cmax 0.19 ng/ml; Fig. 3b).
On day 14, CP-17 baseline concentrations in dermal inter-
stitial fluid of non-lesional skin were not quantifiable. CP-17
levels showed a steep increase resulting in a peak at around
10 h (0.43–4.1 ng/ml, mean Cmax 1.00 ng/ml; Fig. 3a). In
lesional skin, the CP-17 levels were already quantifiable at
baseline (pre-dose), were then transiently dropping to levels
below LLOQ after dosing before moderately increasing to a
peak at 18 h (0.13–1.53 ng/ml, mean Cmax 0.68 ng/ml;
Fig. 3b).
The cumulated quantities (AUC 0–24 h, Table I) after one
day of treatment were 0.854±0.422 ng and 2.142±1.993 ng
in lesional and non-lesional skin, respectively (p=0.033). This
difference was not statistically significant considering the
Bonferroni-adjusted significance level of p = 0.0125.
Corresponding values after 14 days of treatment were in-
creased (2.768±2.010 ng and 4.439±4.602 ng) but more
similar to each other compared to day 1 (p=0.349). In lesional
skin, the AUC-increase compared to day 1 was pronounced
but did not reach statistical significance (p=0.020) considering
Bonferroni. The increase for non-lesional skin was less pro-
nounced (p=0.093). Table I summarizes the AUCs. Notably,
this conventional comparison of AUCs does not yet take the
factor probe depth into account.
Conventional data treatment (values < LLOQ set to
LLOQ or LLOQ/2) resulted in a significant increase of the
mean profiles, in particular for profiles from lesional skin,
which diminished the differences (Figure S1). Thus, when
values<LLOQ were substituted by LLOQ/2, the difference
found between lesional skin and non-lesional skin on day 1 as
well as the increase in lesional skin from day 1 to day 15 did
not reach the level of statistical significance (p=0.057 and
p=0.053, Suppl. Table S2). When substituted by LLOQ,
the level of significance was clearly missed (p=0.111 and
p=0.113, Suppl. Table S3).
Evaluation of Influential Parameters
The dependency of AUCs from depth was indicated by a plot of
AUCs versus probe-depth (Fig. 4). The AUCs of adjacent probe
triplets are clearly related by depth (i.e., negative slopes only),
while the remaining AUC variability is attributed to the individ-
uals as such (i.e., the inter-subject variability of the skin barrier).
Fig. 3 Mean CP-17 concentration
profiles from baseline to 24 h post-
dose on the Day 1 (after 1st dose)
and Day 14 (after 14th dose). (a)
Non-lesional skin profiles. (b)
Lesional skin profiles. Data are
mean± sem.
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Frequency analysis showed that in 23 out of 30 cases (77%),
the deeper probe showed a lower AUC than the more super-
ficial probe. The frequency increased to 89%when the depth-
difference was larger than the ultrasound measurement error
of 0.2 mm. The paired t-test showed a statistically significant
difference in AUC (p< 0.001) between deeper (2.017
± 2.689 ng*h/ml) and more superficial probes (2.938
±3.024 ng*h/ml).
Finally, the linear mixed effects model identified (i) skin
type (lesional versus non-lesional, p=0.0158), (ii) time (day 1
versus day 14, p<0.0001) and (iii) probe depth (p<0.0001) as
statistically significant predictor variables for AUC. The fol-
lowing equations summarize the result of the modelling
process:
Non-lesional skin at Day 1:
AUC ¼ exp 1:725‐1:737* Depthð Þ ð1Þ
Non-lesional skin at Day 14:
AUC ¼ exp 2:554‐1:737* Depthð Þ ð2Þ
Lesional skin at Day 1:
AUC ¼ exp 1:370‐1:737* Depthð Þ ð3Þ
Lesional skin at Day 14:
AUC ¼ exp 2:199‐1:737* Depthð Þ ð4Þ
Figure 5 provides a plot of these equations and their fit to
the underlying AUC data. This representation shows the
differences in AUC between lesional and non-lesional skin
both after the 1st dose and the 14th dose, and the AUC in-
crease by daily topical dosing due to the faster absorption.
DISCUSSION
The intradermal CP-17 concentration profiles assessed in this
study revealed a significantly higher penetration of CP-17 into
non-lesional skin than into lesional psoriatic skin. We also
found that penetration into lesional skin increased with skin
healing and that CP-17 did not significantly accumulate in the
skin regardless of the skin condition. Thus, by using dOFM,
we were able to identify kinetic differences rather than mea-
suring the difference in total quantities only, as has been done
in previous studies using classical sampling methods (4, 6).
Additionally, we identified dOFM probe depth as a relevant
variable to be considered in future topical pharmacokinetic
studies with dOFM or dermal microdialysis.
dOFM proved to be suitable for sampling of highly lipo-
philic drugs because the large openings in the dOFM probe
allowed sampling of the total drug concentration without
any adsorptive losses. This study provided a CP-17 profile
when released from a topically applied low strength cream
(0.05% CP-17). In-depth analysis of the AUCs revealed that
rather minor differences of 0.2 mm in dOFM probe depths
already influence the AUCs observed for CP-17. The iden-
tification of probe depth as a relevant variable indicated that
the overall methodological variation of dOFM is low.
Although the influence of probe depth on kinetics has
Table I AUCs Derived from
Unmodified Data incl. ANOVA
Post-hoc Test on AUC and
Log(AUC)
Group Time N Variable Median Mean SD Day 1 vs. Day 14 L vs. NL
L Day 1 8 AUC 0.732 0.854 0.422 p= 0.020 p= 0.033
L Day 14 8 AUC 2.071 2.768 2.010 p= 0.349
NL Day 1 8 AUC 1.705 2.142 1.993 p= 0.093
NL Day 14 8 AUC 2.521 4.439 4.602
Fig. 4 AUC data of non-lesional
skin on day 1 plotted versus depth.
Regression lines are fitted to the
AUCs of the 3 adjacent probes in
non-lesional skin for each subject.
The illustration indicates a
relationship between the AUCs and
probe depth in 7 of 8 subjects
(negative slopes) and also indicates
that most of the variability is due to
inter-subject variability of CP-17
penetration.
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repeatedly been considered in dermal MD studies (15, 18),
no significant effect has been published yet. Methodological
differences or the different distribution of predominantly
water soluble compounds which have been investigated in
these dermal MD studies could have prevented the identifi-
cation of any impact of probe depth variations. One meth-
odological study found that different depths of the MD
probes yielded different AUCs (19) but the depths
differences were rather large (1 mm) and thus not represen-
tative for standardized use of probes in clinical studies. In
contrast, our study assessed the impact of small inevitable
depth differences occurring during probe insertion in stan-
dardized topical PK studies. We found a statistically signifi-
cant impact of these small depth differences on the mea-
sured CP-17-profiles and this study provided a concentra-
tion versus depth profile for this glucocorticoid. A similar
Fig. 5 AUC0-24 h for CP-17 in dOFM samples on the days 1 and 14 as a function of depth. (a) AUCs of non-lesional skin and (b) AUCs of lesional skin; (c) All
four AUC regression lines from both non-lesional and lesional skin on both day 1 and day 14 (see Eqs. 1–4).
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depth-dependent profile has been shown in the past for top-
ical hydrocortisone by using radio-labelling and slicing
methodology (20).
These results indicate that future dOFM/MD studies
which are comparing the PK of topical formulations, like top-
ical bioequivalence studies, should consider that (i) probe
depths should be precisely measured (by e.g., full length scan-
ning of each probe using a wide angle ultrasound device), (ii) a
potential impact of probe depth should be evaluated and (iii)
any impact should be adequately taken into account in the
representation of the PK outcome variables.
We investigated the kinetic differences of drug concentra-
tions in lesional and non-lesional skin. These kinetic results
shed light on the skin penetration properties of a high-potent
topical glucocorticoid and on the role of the SC in psoriasis for
the absorption of topically applied lipophilic drugs. The pen-
etration of CP-17 into the dermis after the 1st dosing on day 1
was slow as expected and reached Cmax at 18 h in non-lesional
skin. Interestingly, the penetration into lesional skin was even
slower and the measured dermal CP-17 concentrations were
significantly reduced. This is in agreement with a previous
dOFM study that investigated the penetration behavior of
the moderately lipophilic topical drug candidate BCT194
(12). One reason for the lower drug levels measured by
dOFM in the dermis could be the distance between the
dOFM probe and the SC barrier in the inflamed and thus
highly blood-perfused dermis, but lower drug levels in lesional
skin were also found by tape stripping and skin punch biopsy
from in vitro and clinical studies (Rony et al., unpublished data
presented at Groupe de Métabolisme et Pharmacocinétique -
Meeting 2011, Paris). Rony et al. showed that 70–80% of the
penetrated dose has been recovered in the SC in healthy skin,
while in psoriatic skin at least 95% of the penetrated dose has
been recovered in the SC. Less than 1% of the applied dose
reached the deeper skin layers, such as epidermis and dermis,
which is the site of drug action. The authors concluded that in
psoriasis the hyperkeratosed SC seems to absorb higher
amounts of the topical drug and therefore acts as a trap
compartment. However, this study assessed drug penetration
and distribution only at one single point in time and thus does
not allow the investigation of transdermal penetration kinetics
to reveal the role of SC in topical drug release. Nevertheless,
their data and the results from our study are in contrast to the
common assumption that diseased skin is more permeable for
topical drugs. Recent reviews of in vitro (21) and in vivo studies
(22) concluded that permeation through damaged skin is mod-
estly increased at least for hydrophilic compounds, but studies
on psoriatic skin are scarce. One cited study found that psori-
atic and unaffected skin showed similar permeability to hydro-
cortisone, a glucocorticoid less lipophilic than CP-17 (23).
Based on this study it has been suggested that psoriasis might
not have a penetration barrier defect or that the penetration of
lipophilic compounds is not influenced by damaged skin (22).
In conclusion, our dOFM data clearly showed that the per-
meability of the SC barrier is not impaired for topical drug
penetration in psoriasis but may instead act as a trap compart-
ment and thus impact the penetration rate for many of the
predominantly lipophilic topical drugs.
The low baseline levels on day 14 of our study indicate that,
irrespective of the skin condition, CP-17 does not significantly
accumulate in the dermis following repeated dosing.
Following the 14th dose, the dermal CP-17 concentrations
increased significantly faster in lesional skin, but also some-
what faster in non-lesional skin compared to day 1. For
lesional skin, the significantly increased absorption on day 14
can be explained by the ongoing healing of the skin leading to
a partial normalization (thinning) of the thickened psoriatic
SC. Faster penetration into non-lesional skin on day 14 can
be explained by the well-known side effect of prolonged top-
ical glucocorticoid therapy that leads to steroid atrophy of the
skin (24–26). Noteworthy, the intradermal CP-17 levels on
day 14 did not return to baseline after 24 h due to the fact
that the cream on this study day has not been removed after
approximately 4 h but remained on the skin.
The clinical effects of a glucocorticoid therapy were con-
firmed by the significantly decreased total sum scores (TSS)
for the treated sites, which were also well demarked as white
zones within the plaques. This observation is consistent with
the well-known skin blanching response of topical corticoste-
roids (27).
The intradermal sampling of CP-17 was challenging as
indicated by the low concentrations where Cmax did not ex-
ceed the 3-fold LLOQ. In the explorative data analysis we
either accepted values below LLOQ or substituted them by
a standard value (LLOQ or LLOQ/2) and the results dem-
onstrated that standardized raw data treatment should be
used with caution in particular for slow penetrating drugs, as
it may bias the data.
A major challenge was the cleaning of the probe insertion
sites on day 14 to prevent the contamination of the probes by
residual concentrations in the SC. The increased baseline and
initial post-dose values in lesional skin on day 14 indicated that
the cleaning measures were not sufficient. Therefore, in stud-
ies including insertion of probes in topically treated skin, the
skin cleaning procedure should be further improved, or Band-
Aids should be used during the treatment phase to prevent a
carry-over of the drug to skin outside the treatment site when
the volunteers are at home. We found considerable inter-
subject variability regarding the penetration and the dermal
drug levels especially in psoriatic lesions. High inter-sub-
ject variability in skin permeability has also been observed
clinically (13).
Our study has provided intradermal kinetic data of a top-
ical drug in vivo in humans with a time and depth related
resolution, when released from a low-strength product. This
al lows experimental verif ication of mathematical
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physiological models for topical drug penetration (28, 29). To
support these models, further topical drugs with different lipo-
philicity and protein binding properties should be investigat-
ed. The dOFM approach is well tolerated by healthy subjects
and psoriatic patients and it recovers the total drug concen-
tration directly at the site of action. This approach may have a
general utility across the entire range of topical dermatological
drug products, including early head-to-head testing of formu-
lations in humans when dosed in low quantities as well as
head-to-head topical bioequivalence studies of generic versus
reference listed drug products. Moreover, since dOFM sam-
ples represent diluted but otherwise unfiltered dermal intersti-
tial fluid, dOFM samples also include intradermal biomarkers
which can be analyzed based on novel highly sensitive low-
volume cytokine assays. Hence, future studies can be per-
formed as combined pharmacokinetic and pharmacodynamic
studies.
CONCLUSION
In conclusion, the dermal pharmacokinetics of highly lipophil-
ic CP-17 released from a commercial low-strength cream in
patients in vivo was successfully assessed by dOFM and time as
well as depth (i.e., spatially) resolved kinetic data were deliv-
ered. These data showed that CP-17 does not significantly
accumulate in the dermis following repeated topical dosing
and revealed a reduced penetration rate of the high-potent
glucocorticoid into hyperkeratosed psoriatic skin. Therefore,
our data support the assumption that the thickened SC of
psoriatic skin acts as trap compartment for lipophilic topical
drugs. In terms of methodological advancements our study
shows the utility of dOFM to support the clinical development
of new drugs by facilitating studies with short treatment dura-
tion and low drug amount at early stages with limited preclin-
ical prerequisites. Demonstrating the high spatial resolution of
the dOFM sampling probes, our study provides essential in-
formation for the proper design and interpretation of topical
bioequivalence studies.
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